Cargando…
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)
BACKGROUND: The presence of KRASG12C mutation in metastatic colorectal cancer (mCRC) correlates with poor outcome. Although different selective inhibitors are under clinical development, the optimal treatment remains uncertain. Thus, we conducted a retrospective analysis in a large cohort of patient...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588891/ https://www.ncbi.nlm.nih.gov/pubmed/35994791 http://dx.doi.org/10.1016/j.esmoop.2022.100567 |
_version_ | 1784814173725655040 |
---|---|
author | Ciardiello, D. Chiarazzo, C. Famiglietti, V. Damato, A. Pinto, C. Zampino, M.G. Castellano, G. Gervaso, L. Zaniboni, A. Oneda, E. Rapisardi, S. Bordonaro, R. Zichi, C. De Vita, F. Di Maio, M. Parisi, A. Giampieri, R. Berardi, R. Lavacchi, D. Antonuzzo, L. Tamburini, E. Maiorano, B.A. Parrella, P. Latiano, T.P. Normanno, N. De Stefano, A. Avallone, A. Martini, G. Napolitano, S. Troiani, T. Martinelli, E. Ciardiello, F. De Vita, F. Maiello, E. |
author_facet | Ciardiello, D. Chiarazzo, C. Famiglietti, V. Damato, A. Pinto, C. Zampino, M.G. Castellano, G. Gervaso, L. Zaniboni, A. Oneda, E. Rapisardi, S. Bordonaro, R. Zichi, C. De Vita, F. Di Maio, M. Parisi, A. Giampieri, R. Berardi, R. Lavacchi, D. Antonuzzo, L. Tamburini, E. Maiorano, B.A. Parrella, P. Latiano, T.P. Normanno, N. De Stefano, A. Avallone, A. Martini, G. Napolitano, S. Troiani, T. Martinelli, E. Ciardiello, F. De Vita, F. Maiello, E. |
author_sort | Ciardiello, D. |
collection | PubMed |
description | BACKGROUND: The presence of KRASG12C mutation in metastatic colorectal cancer (mCRC) correlates with poor outcome. Although different selective inhibitors are under clinical development, the optimal treatment remains uncertain. Thus, we conducted a retrospective analysis in a large cohort of patients with KRASG12C mCRC treated in 12 Italian oncology units. PATIENTS AND METHODS: Patients with unresectable mCRC harboring KRASG12C mutation receiving a first-line chemotherapy doublet or triplet between 2011 and 2021 were included in the study. Evaluation of overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) analysis was carried out. RESULTS: A total of 256/6952 (3.7%) patients with mCRC displayed KRASG12C mutation; of these, 111 met the inclusion criteria. The ORR of first-line therapy was 38.7% (43/111). Median PFS (mPFS) was 9 months [95% confidence interval (CI) 7.5-10.5 months]. After progression, only 62% and 36% of the patients are fit to receive second or third lines of treatment, with limited clinical benefit. Median OS (mOS) was 21 months (95% CI 17.4-24.6 months). In patients receiving first-line triplet chemotherapy, ORR was 56.3% (9/16), mPFS was 13 months (95% CI 10.3-15.7 months) and mOS was 32 months (95% CI 7.7-56.3 months). For irinotecan-based doublets, ORR was 34.5 (10/29), mPFS was 9 months (95% CI 6.4-11.6 months) and mOS was 22 months (95% CI 16.0-28.0 months). With oxaliplatin-based doublets ORR was 36.4% (24/62), mPFS was 7 months (95% CI 4.6-9.4 months) and mOS was 18 months (95% CI, 13.6-22.4 months). CONCLUSION: Patients with KRASG12C-mutant mCRC had a disappointing response to standard treatments. Within the limitations of a retrospective study, these results suggest that first-line chemotherapy intensification with FOLFOXIRI is a valid option in fit patients. |
format | Online Article Text |
id | pubmed-9588891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-95888912022-10-25 Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) Ciardiello, D. Chiarazzo, C. Famiglietti, V. Damato, A. Pinto, C. Zampino, M.G. Castellano, G. Gervaso, L. Zaniboni, A. Oneda, E. Rapisardi, S. Bordonaro, R. Zichi, C. De Vita, F. Di Maio, M. Parisi, A. Giampieri, R. Berardi, R. Lavacchi, D. Antonuzzo, L. Tamburini, E. Maiorano, B.A. Parrella, P. Latiano, T.P. Normanno, N. De Stefano, A. Avallone, A. Martini, G. Napolitano, S. Troiani, T. Martinelli, E. Ciardiello, F. De Vita, F. Maiello, E. ESMO Open Original Research BACKGROUND: The presence of KRASG12C mutation in metastatic colorectal cancer (mCRC) correlates with poor outcome. Although different selective inhibitors are under clinical development, the optimal treatment remains uncertain. Thus, we conducted a retrospective analysis in a large cohort of patients with KRASG12C mCRC treated in 12 Italian oncology units. PATIENTS AND METHODS: Patients with unresectable mCRC harboring KRASG12C mutation receiving a first-line chemotherapy doublet or triplet between 2011 and 2021 were included in the study. Evaluation of overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) analysis was carried out. RESULTS: A total of 256/6952 (3.7%) patients with mCRC displayed KRASG12C mutation; of these, 111 met the inclusion criteria. The ORR of first-line therapy was 38.7% (43/111). Median PFS (mPFS) was 9 months [95% confidence interval (CI) 7.5-10.5 months]. After progression, only 62% and 36% of the patients are fit to receive second or third lines of treatment, with limited clinical benefit. Median OS (mOS) was 21 months (95% CI 17.4-24.6 months). In patients receiving first-line triplet chemotherapy, ORR was 56.3% (9/16), mPFS was 13 months (95% CI 10.3-15.7 months) and mOS was 32 months (95% CI 7.7-56.3 months). For irinotecan-based doublets, ORR was 34.5 (10/29), mPFS was 9 months (95% CI 6.4-11.6 months) and mOS was 22 months (95% CI 16.0-28.0 months). With oxaliplatin-based doublets ORR was 36.4% (24/62), mPFS was 7 months (95% CI 4.6-9.4 months) and mOS was 18 months (95% CI, 13.6-22.4 months). CONCLUSION: Patients with KRASG12C-mutant mCRC had a disappointing response to standard treatments. Within the limitations of a retrospective study, these results suggest that first-line chemotherapy intensification with FOLFOXIRI is a valid option in fit patients. Elsevier 2022-08-19 /pmc/articles/PMC9588891/ /pubmed/35994791 http://dx.doi.org/10.1016/j.esmoop.2022.100567 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Ciardiello, D. Chiarazzo, C. Famiglietti, V. Damato, A. Pinto, C. Zampino, M.G. Castellano, G. Gervaso, L. Zaniboni, A. Oneda, E. Rapisardi, S. Bordonaro, R. Zichi, C. De Vita, F. Di Maio, M. Parisi, A. Giampieri, R. Berardi, R. Lavacchi, D. Antonuzzo, L. Tamburini, E. Maiorano, B.A. Parrella, P. Latiano, T.P. Normanno, N. De Stefano, A. Avallone, A. Martini, G. Napolitano, S. Troiani, T. Martinelli, E. Ciardiello, F. De Vita, F. Maiello, E. Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) |
title | Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) |
title_full | Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) |
title_fullStr | Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) |
title_full_unstemmed | Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) |
title_short | Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) |
title_sort | clinical efficacy of sequential treatments in krasg12c-mutant metastatic colorectal cancer: findings from a real-life multicenter italian study (crc-kr goim) |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588891/ https://www.ncbi.nlm.nih.gov/pubmed/35994791 http://dx.doi.org/10.1016/j.esmoop.2022.100567 |
work_keys_str_mv | AT ciardiellod clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT chiarazzoc clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT famigliettiv clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT damatoa clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT pintoc clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT zampinomg clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT castellanog clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT gervasol clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT zanibonia clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT onedae clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT rapisardis clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT bordonaror clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT zichic clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT devitaf clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT dimaiom clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT parisia clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT giampierir clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT berardir clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT lavacchid clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT antonuzzol clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT tamburinie clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT maioranoba clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT parrellap clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT latianotp clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT normannon clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT destefanoa clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT avallonea clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT martinig clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT napolitanos clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT troianit clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT martinellie clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT ciardiellof clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT devitaf clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim AT maielloe clinicalefficacyofsequentialtreatmentsinkrasg12cmutantmetastaticcolorectalcancerfindingsfromareallifemulticenteritalianstudycrckrgoim |